Agile Therapeutics, Inc. (AGRX) to Post FY2017 Earnings of ($0.96) Per Share, William Blair Forecasts

Agile Therapeutics, Inc. (NASDAQ:AGRX) – Research analysts at William Blair boosted their FY2017 earnings estimates for Agile Therapeutics in a research report issued on Tuesday. William Blair analyst T. Lugo now expects that the specialty pharmaceutical company will post earnings per share of ($0.96) for the year, up from their previous estimate of ($1.03). William Blair also issued estimates for Agile Therapeutics’ Q4 2017 earnings at ($0.22) EPS and FY2018 earnings at ($0.56) EPS.

A number of other equities analysts also recently issued reports on the company. Royal Bank Of Canada set a $8.00 price target on Agile Therapeutics and gave the stock a “buy” rating in a research note on Sunday, July 16th. HC Wainwright began coverage on Agile Therapeutics in a research note on Wednesday, July 19th. They issued a “buy” rating and a $10.00 price target on the stock. Janney Montgomery Scott restated a “buy” rating and issued a $15.00 price target on shares of Agile Therapeutics in a research note on Friday, July 21st. Noble Financial restated a “buy” rating on shares of Agile Therapeutics in a research note on Sunday, July 30th. Finally, ValuEngine downgraded Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Agile Therapeutics presently has a consensus rating of “Buy” and an average price target of $10.20.

WARNING: This story was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://stocknewstimes.com/2017/11/11/agile-therapeutics-inc-agrx-to-post-fy2017-earnings-of-0-96-per-share-william-blair-forecasts.html.

Shares of Agile Therapeutics (NASDAQ:AGRX) opened at $4.59 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.10 and a quick ratio of 3.37. Agile Therapeutics has a 52 week low of $1.82 and a 52 week high of $7.39.

Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03.

In other news, Chairman Alfred Altomari purchased 10,000 shares of the company’s stock in a transaction dated Friday, August 25th. The shares were purchased at an average cost of $3.34 per share, for a total transaction of $33,400.00. Following the purchase, the chairman now directly owns 161,587 shares in the company, valued at approximately $539,700.58. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 3.50% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC purchased a new position in shares of Agile Therapeutics in the 2nd quarter worth $122,000. Franklin Resources Inc. lifted its position in Agile Therapeutics by 39.2% during the second quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock valued at $10,396,000 after purchasing an additional 780,578 shares in the last quarter. Susquehanna International Group LLP purchased a new position in Agile Therapeutics during the second quarter valued at $205,000. Royce & Associates LP lifted its position in Agile Therapeutics by 1.1% during the second quarter. Royce & Associates LP now owns 998,582 shares of the specialty pharmaceutical company’s stock valued at $3,745,000 after purchasing an additional 11,000 shares in the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in Agile Therapeutics during the third quarter valued at $467,000. Hedge funds and other institutional investors own 67.52% of the company’s stock.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply